HEPCLUDEX 2mg powder for solution for injection GILEAD ORIGINAL MEDICINE
Chemical substance: bulevirtide
ATC code: J05AX28 • Antiinfectives for systemic use | Direct acting antivirals | Other antivirals
Active substance
Results for the substance bulevirtide
1 result
About this active substance
Bulevirtide is a medication used for the treatment of chronic hepatitis delta virus (HDV) infection in adult patients with compensated liver disease. HDV is a rare but severe viral infection that occurs only in individuals infected with hepatitis B virus (HBV). Bulevirtide works by blocking the entry of the virus into hepatocytes, thereby reducing viral replication and the progression of liver disease.
The medication is administered as a subcutaneous injection, usually once daily, as directed by a doctor. The treatment requires regular monitoring to assess efficacy and detect potential adverse effects.
Common side effects include injection site reactions, elevated liver enzyme levels, and fatigue. In rare cases, severe allergic reactions or worsening of liver disease may occur.
Bulevirtide is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about all medications they are taking to avoid drug interactions. Additionally, it is important for patients to continue monitoring for HBV infection, as treatment with bulevirtide does not completely eliminate the risk of HBV-related complications.
The medication is administered as a subcutaneous injection, usually once daily, as directed by a doctor. The treatment requires regular monitoring to assess efficacy and detect potential adverse effects.
Common side effects include injection site reactions, elevated liver enzyme levels, and fatigue. In rare cases, severe allergic reactions or worsening of liver disease may occur.
Bulevirtide is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about all medications they are taking to avoid drug interactions. Additionally, it is important for patients to continue monitoring for HBV infection, as treatment with bulevirtide does not completely eliminate the risk of HBV-related complications.